SELLAS Life Sciences Group, Inc., an advanced-stage biopharmaceutical company, focuses on the development of new cancer immunotherapies for various indications of cancer in the United States. The company is headquartered in New York, New York.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 900,000 |
| EBITDA | — |
| Operating Margin | 0.00% |
| Return on Equity | -39.60% |
| Return on Assets | -23.30% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.59 |
| Price-to-Book | 18.73 |
| Price-to-Sales (TTM) | 26.90 |
| EV/Revenue | 20.84 |
| EV/EBITDA | -1.71 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -82.50% |
| Shares Outstanding | $201.95M |
| Float | $201.15M |
| % Insiders | 0.92% |
| % Institutions | 36.65% |
Volatility is currently contracting
SELLAS Life Sciences Group is a high-conviction buy ahead of the pivotal Phase 3 REGAL trial readout for GPS in AML. The unusually long REGAL trial timeline suggests GPS may be delivering a meaningful survival benefit in a high-unmet-need AML population. SLS is well-funded into 2027, with $138.3 million in cash and targeted spending aligned to upcoming binary catalysts.
- Final Analysis of Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia to be Conducted Following the 80 th Event - - 28 Patients Enrolled in Phase 2 Trial of SLS009 in Newly Diagnosed First-Line AML; Topline Data Expected in Q4 2026 - - Strong Preclinical Indications of Efficacy of SLS009 in Advanced Pancreatic Cancer Resistant to RAS inhibitors, Clinical Development Preparations Ongoing - - $138.3 Million in Cash and Cash Equivalents as of June 30, 2026 - NEW YORK, Aug. 11, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today reported financial results for the second quarter ended June 30, 2026, and provided a corporate update. “The second quarter was an important period of execution for SELLAS as we continued to advance both of our lead clinical programs, GPS and SLS009,” said Angelos Stergiou, MD, ScD h.c.
SELLAS Life Sciences is at the center of a debate over its event-driven Phase 3 REGAL trial for GPS in AML CR2 patients. The extended REGAL timeline should not be interpreted as evidence of failure or success, given its event-driven design and recent protocol amendments. FDA-approved unlimited dosing and continued management confidence add nuance, but only final data will determine REGAL's outcome.
Sellas Life Sciences (SLS) shares are extending gains on Jun. 26 following a key regulatory filing that disclosed a series of comprehensive corporate amendments regarding executive compensation and protection. Specifically, the board restructured change-of-control and severance agreements for CEO Angelos Stergiou, CFO John Burns, and CDO Dragan Cicic.
NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS, will participate in the following upcoming investor conferences: 2026 Stifel Virtual Targeted Oncology Forum Format: Corporate Presentation and Fireside Chat Date and Time: Tuesday, May 19, 2026, at 2:00 PM ET Location: New York, NY Webcast Link: Click here A.G.P.
– Contract Research Organization for the Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) Informed the Company that 78 Events have Occurred in the Trial as of May 11, 2026; SELLAS Remains Blinded to Trial Outcomes – – Final Analysis of REGAL Trial of GPS in AML to be Conducted Following the 80 th Event – – Ongoing Dosing of Patients in Phase 2 Trial of SLS009 in Newly Diagnosed First Line AML – – $107.1 Million in Cash and Cash Equivalents as of March 31, 2026; Additional $7.5 Million in Proceeds Received in Q2 2026 to Date through Warrant Exercises – NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today reported financial results for the first quarter ended March 31, 2026, and provided a corporate update. “The first quarter of 2026 marked an important period for SELLAS as we continued to execute across our clinical programs while preparing for the anticipated pivotal Phase 3 REGAL trial data readout,” said Angelos Stergiou, MD, ScD h.c.
SELLAS Life Sciences is rated 'Hold' due to pending phase 3 REGAL data for GPS in AML after CR2, a major 2026 catalyst. The company's GPS targets WT1 in AML, with prior phase 1/2 data showing a median OS of 21 months versus 5.4 months for standard therapy. Interim REGAL analysis showed fewer than 50% deceased at 13.5 months; final analysis at 80 events expected in 1H 2026.
The mean of analysts' price targets for SELLAS Life Sciences Group, Inc. (SLS) points to a 66.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
The consensus price target hints at a 63.6% upside potential for SELLAS Life Sciences Group, Inc. (SLS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on SLS and any ticker you trade — then tracks every position and per-strategy win rate.
